Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPF-001 in Inherited Erythromelalgia
NCT01090622Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2010
- Primary completion
- Aug 2010
- Countries
- 1
- Sponsor
- Xenon Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- funapide
- Conditions
- erythromelalgia
01
Overview
Phase 2, randomised, double-blind trial in erythromelalgia comparing XPF-001 with Matching Placebo (2 arms). Primary endpoint: Pain intensity difference at 2 days. Started Apr 2010; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
XPF-001
XPF-001 Oral capsule
Matching Placebo
Placebo Oral capsule
03
Who it enrols
Adult patients with inherited erythromelalgia and moderate pain, generally healthy otherwise.
04
Endpoints
Primary
Pain intensity difference
Beyond the preview
Go deeper on NCT01090622.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090622.